天冬氨酸转氨酶与血小板比值指数对非急诊大范围肝切除术后结局的预后作用
基于美国外科医师学会国家手术质量改进计划2014-2021年数据,纳入8,933例非急诊大范围肝切除且无病毒性肝炎、无腹水的患者,1,170例(13.1%)APRI≥0.7。APRI≥0.7是围术期输血、总体并发症和30天死亡的独立预测因素,或可无创用于术前风险分层。
要点
- 非急诊大范围肝切除患者中APRI≥0.7占13.1%,与围术期输血、总体并发症及30天死亡独立相关。
- APRI≥0.7者围术期输血风险增加(OR 1.51),总体并发症风险增加(OR 1.16),死亡风险增加(OR 1.56)。
- 围术期输血本身是总体并发症、严重并发症和死亡的独立预测因素,提示APRI可能通过输血路径影响结局。
核心结论
- APRI≥0.7与非急诊大范围肝切除术后的围术期输血、总体并发症和30天死亡独立相关。
- APRI或可作为无创工具用于择期大范围肝切除术前风险分层。
研究设计与样本
- 回顾性队列研究,数据来自美国外科医师学会国家手术质量改进计划(ACS NSQIP)2014-2021年。
- 纳入非急诊大范围肝切除患者,排除急诊手术、病毒性肝炎和腹水患者,最终分析8,933例。
- APRI计算公式为(天冬氨酸转氨酶/40)/血小板计数×100,以APRI≥0.7定义显著纤维化。
- 采用单因素分析筛选相关因素,多因素logistic回归识别校正后的独立预测因素。
主要发现
- 8,933例中1,170例(13.1%)APRI≥0.7。
- 围术期输血2,497例(28.0%),总体并发症3,195例(35.8%),严重并发症2,665例(29.8%),30天死亡238例(2.7%)。
临床怎么用
- 对拟行择期大范围肝切除、无病毒性肝炎的患者,术前可计算APRI,若≥0.7提示围术期输血、并发症和死亡风险较高。
- APRI≥0.7可作为术前风险分层的参考指标,辅助识别需要优化围术期管理的患者。
局限性
- 回顾性研究设计,仅能提示关联而非因果关系。
- 数据来自ACS NSQIP数据库,可能存在未测量混杂因素。
- 研究排除了病毒性肝炎和腹水患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Noninvasive screening methods to identify patients preoperatively with abnormal liver texture remain limited. Aspartate transaminase to platelet ratio index has been validated to predict fibrosis in patients with hepatitis C; however, its use as a predictor of postoperative outcomes in patients without viral hepatitis remains unknown. METHODS: We queried the American College of Surgeons National Surgical Quality Improvement Program dataset to identify patients who underwent a major hepatectomy between 2014 and 2021. We excluded patients who underwent emergent operations, patients with viral hepatitis, and patients with ascites. Aspartate transaminase to platelet ratio index was calculated using the following equation: (aspartate transaminase/40)/(platelet count) × 100. An aspartate transaminase to platelet ratio index ≥0.7 was used to identify patients with significant fibrosis. Univariable analysis was performed to identify factors associated with aspartate transaminase to platelet ratio index ≥0.7, perioperative transfusion, serious morbidity, overall morbidity, and 30-day mortality. Multivariable logistic regression analysis was performed to identify adjusted predictors of these outcomes. RESULTS: Of the 8,933 patients who met inclusion criteria, 1,170 (13.1%) patients had an aspartate transaminase to platelet ratio index ≥0.7. A perioperative blood transfusion was administered to 2,497 (28.0%). The number of patients who experienced overall morbidity, serious morbidity, and mortality were 3,195 (35.8%), 2,665 (29.8%), and 238 (2.7%), respectively. Aspartate transaminase to platelet ratio index ≥0.7 was an independent predictor of transfusion (odds ratio: 1.51 [1.32-1.72], P < .001), overall morbidity (1.16 [1.01-1.33], P = .032), and mortality (1.56 [1.12-2.13], P = .006). Transfusion was an independent predictor of overall morbidity (2.50 [2.26-2.76], P < .001), serious morbidity (2.51 [2.26-2.79], P < .001), and mortality (3.28 [2.49-4.33], P < .001). CONCLUSION: An aspartate transaminase to platelet ratio index ≥0.7 is associated with perioperative transfusion, overall morbidity, and 30-day mortality. The aspartate transaminase to platelet ratio index may serve as a noninvasive tool to risk stratify patients before elective major hepatectomy.
引用
- Patel DJ, LeCompte MT, Kim HJ, et al. The prognostic role of aspartate transaminase to platelet ratio index on outcomes after nonemergent major hepatectomy. Surgery. 2024. PMID: 38987095. doi:10.1016/j.surg.2024.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。